<DOC>
	<DOCNO>NCT01121016</DOCNO>
	<brief_summary>Hypothesis : Add-on therapy oral montelukast ( Mon ) inhale budesonide ( BUD ) may achieve good control cough cause nonasthmatic eosinophilic bronchitis ( NAEB ) fast reduction airway eosinophilia . Objective : To evaluate efficacy add-on therapy Mon inhale corticosteroid ( ICS ) treatment adult patient chronic/subacute cough cause NAEB diagnose outpatient setting . Primary endpoint：cough severity rat cough visual analogue score ( VAS ) 1 eosinophil count induce sputum 4-week BUD monotherapy Mon adjunct therapy .</brief_summary>
	<brief_title>Efficacy Safety add-on Montelukast Inhaled Budesonide Treatment Nonasthmatic Eosinophilic Bronchitis</brief_title>
	<detailed_description>Subjects：63 newly-diagnosed , steroid-naïve adult patient chronic subacute cough cause NAEB . Grouping：ICS monotherapy ( 21 patient , BUD，400mcg mcg , twice daily+ placebo , 4 wks ) ; Mon adjunct therapy ( 42 patient , Mon 10mg daily + BUD 400mcg twice daily 4wks ) . Protocol Day 1 : In respiratory specialist clinic , diagnosis NAEB establish follow 2006 ACCP guideline ( sputum eosinophilia &gt; 3 % , negative chest radiography , spirometry bronchial provocation test ) . After brief , eligible subject give informed write consent , randomly allocate different treatment group . Patients ' demographical data , course nature cough , accompany symptom upper respiratory comorbidities , skin prick test common aeroallergens1 , baseline cough VAS ( 0-100 mm ) 1 , spirometry induce sputum cell count , record manage physician case record file ( CRF ) . Pulmicort Turbuhaler ( AstraZeneca , budesonide 100 mcg/dose X 200 dos ) prescribe patient . Day 2 : Before initiation treatment , Office Clinical Trials , staff member instruct patient correct usage ICS , disperse Mon tablets placebo well daily record card , explain record daily use ICS Mon , adverse event . Once treatment initiated , oral steroid , ICS , anti-histamines , beta-2 agonist theophylline prescribe use throughout study period . Day 8、15：Revisits : Patients ' nature cough , accompany symptom , cough VAS , induce sputum cell count reevaluate recorded CRF . Old daily record card collect . New one well Mon tablet placebo give . Patients ' skill use ICS , compliance , systemic local adverse event monitor . Day 29： Revisit : Patients ' nature cough , accompany symptom , cough VAS , spirometry , bronchial provocation test , induce sputum cell count reevaluate recorded CRF . Old daily record card collect . Patients ' skill use ICS , compliance , systemic local adverse event record .</detailed_description>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Adult nonsmoking NAEB patient Without history take Mon , oral inhaled corticosteroid , Without bacterial viral respiratory infection within 30 day prior diagnosis NAEB Current smoker Pregnant lactate woman Known allergy Mon , oral inhaled corticosteroid Unable use ICS follow repeat instruction Complicated unresectable malignancy severe heart , lung , liver kidney disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>NAEB , chronic cough , montelukast , induce sputum</keyword>
</DOC>